No Monitoring needed if there are no Storage Conditions on the Outer Packaging?
Recommendation
14-16 May 2025
Two-day training + 1-day Airport tour at Vienna Airport in cooperation with DHL
Register now for ECA's GMP Newsletter
"Is it acceptable that storage conditions are not monitored for medicinal products which do not have any predefined storage conditions on the outer packaging?" This question was the first GDP-related question being published along with an answer in the Q&A Section of EMA's website.
And EMA gives a clear answer: "No".
The justification is based on the Guideline on declaration of storage conditions (CPMP/QWP/609/96 Rev. 2). If a marketing authorisation holder (MAH) does not want to include storage conditions on the labelling, the MAH at least will need to provide stability data for storage conditions at 25°C / 60% relative humidity (RH), or 30°C / 65% RH (long term) and 40°C / 75% RH (accelerated). This stability data is based on the temperature and humidity conditions of climate zone I (temperate) and II (Mediterranean/subtropical) in Europe.
As a consequence, controls should be in place to maintain conditions relevant to these climate zones, if no labelling statement is given. This means that the temperature should be monitored during storage and transport.
Related GMP News
11.03.2025USP Publishes Summary of Comments on Chapter <1079.2> Regarding Mean Kinetic Temperature (MKT)
11.03.2025EMA: No further Extension of GDP Certificates in 2025
11.03.2025Aide-Mémoires and Checklists in GDP Audits - Benefits and Risks
13.02.2025MHRA updates Guidance on Sourcing Medicines for the UK Market
13.02.2025First GDP Non-Compliance Report of 2025: Data Integrity Issues at Hungarian Wholesaler